AGLE insider filings

Spyre Therapeutics, Inc. — 15 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-11-28. Screen AGLE transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for AGLE between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.

Recent insider filings — Spyre Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2023-11-284Fairmount Funds Management LLC — Director, 10% owner
Fairmount Healthcare Fund L.P. — Director, 10% owner
Fairmount Healthcare Fund II L.P. — Director, 10% owner
Fairmount Healthcare Co-Invest L.P. — Director, 10% owner
Kiselak Tomas — Director, 10% owner
Harwin Peter Evan — Director, 10% owner
Conversion (C): 3,435,480 @ $0 · Conversion (C): 85,887 (derivative) @ $0EDGAR
2023-11-274Albers Jeffrey W. — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-11-274Stelzer Laurie — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2023-11-274Turtle Cameron — Chief Executive Officer, DirectorConversion (C): 723,440 @ $0 · Grant/award (A): 374,000 (derivative) @ $0 · Conversion (C): 18,086 (derivative) @ $0EDGAR
2023-09-054King-Jones Heidy — See RemarksGrant/award (A): 13,495,255 (derivative) @ $0EDGAR
2023-09-054Burrows Scott L — Chief Financial OfficerGrant/award (A): 10,121,441 (derivative) @ $0EDGAR
2023-06-304Alspaugh Jonathan — President and CFOGrant/award (A): 19,787,969 (derivative) @ $0EDGAR
2023-06-304Smith Hunter C — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Lawton Alison Frances — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Cox Russell J. — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-06-304Magovcevic-Liebisch Ivana — DirectorGrant/award (A): 1,950,000 (derivative) @ $0EDGAR
2023-02-244Neuman Linda L — Chief Medical OfficerGrant/award (A): 550,000 (derivative) @ $0EDGAR
2023-02-244Kastenmayer James Paul — General CounselGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-244Hanley Jr. Michael Conick — Chief Business OfficerGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-02-244Alspaugh Jonathan — Chief Financial OfficerGrant/award (A): 640,000 (derivative) @ $0EDGAR

Recent 8-K events — Spyre Therapeutics, Inc.

FiledFormItems reportedSource
2026-10-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-088-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-258-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-158-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-018-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-298-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-168-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-138-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AGLE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →